At a glance
ClinicalIndex Comparison RecordPhase 3Active· 444 enrolled
Drug / intervention
Placebo +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE 2)
In Brief
A Phase 3 clinical trial evaluating Placebo and Risankizumab for Psoriatic Arthritis (PsA). Active but no longer recruiting, targeting 444 participants across 138 sites in 25 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis (PsA)
CountriesArgentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3ActiveOverdue
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartMar 2019
Primary CompletionJun 2020
Study CompletionJun 2026
TodayJul 2026
First PostedSep 14, 2018
Enrollment StartMar 7, 2019
Primary CompletionJun 22, 2020
Study CompletionJun 1, 2026
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.8 years ago
Interventions
Placebobiological
Placebo for risankizumab administered by subcutaneous (SC) injection
Risankizumabbiological
Risankizumab administered by subcutaneous (SC) injection